N4 PHARMA PLC

Report Publication Announcement • Mar 12, 2025

National Storage Mechanism | Additional information

RNS Number : 2499A

Ananda Pharma PLC

12 March 2025

12 March 202 5

ANANDA PHARMA PLC

("Ananda" or the "Company")

Ananda to present at Master Investor Show in London

Ananda Pharma plc (AQSE: ANA), a UK-based biopharmaceutical company developing regulatory approved, cannabinoid medicines to treat complex, chronic conditions, is pleased to announce that its leadership team will be presenting the Ananda Pharma opportunity at the Master Investor Show in London at The Business Design Centre, 52 Upper Street, London N1 0QH, on Saturday, 29th March. Ananda will be present all day at booth M:35.

Jeremy Sturgess-Smith, Finance Director will be presenting on the Showcase stage at 10:25, the Company will also be exhibiting at Booth M:35 throughout the day and Melissa Sturgess, CEO will also be attending the event all day.

Melissa Sturgess, CEO, commented: "We are very much looking forward to participating in Master Investor again this year. It is a great opportunity to speak to existing and potential new shareholders about our drive to bring cannabis based, regulatory approved medicines to the market. We invite everyone to come and say hello at our Booth, number M:35."

To register for the Master Investor Show, please use the following link: https://masterinvestorshow-2025.reg.buzz/?exhibitor-inviter=848eac18-dfd9-11ef-99be-000000000000

About Ananda Pharma

Ananda Pharma (AQSE: ANA) is a UK-based biopharmaceutical company developing regulatory approved, cannabinoid medicines to treat complex, chronic conditions, including epilepsy (trials funded by NHS England and NIHR), endometriosis (funded by NHS Scotland) and chemotherapy pain (funded by NIHR).  The Company is led by successful entrepreneurs and is working with a team of world-class scientists, including globally respected Key Opinion Leaders at the University of Edinburgh, Great Ormond Street Hospital for Children and University College London.

To stay abreast of the latest developments at Ananda, we encourage you to follow our social media channels which are:  

·              Investor Hub: https://investors.anandapharma.co.uk/s/ea8f93

·              Instagram: https://www.instagram.com/anandapharmaplc/

·              LinkedIn :   https://www.linkedin.com/company/anandapharma

·              X : https://twitter.com/AnandaPlc

-Ends-

The Directors of the Company accept responsibility for the contents of this announcement.

For more information please contact:

ANANDA PHARMA PLC Chief Executive Officer Melissa Sturgess Finance Director Jeremy Sturgess-Smith	+44 (0)7463 686 497 jss@anandapharma.co.uk
SP ANGEL CORPORATE FINANCE LLP Corporate Finance Richard Morrison Josh Ray	+44 (0)20 3470 0470
Corporate Broking Abigail Wayne Rob Rees
YELLOW JERSEY PR Sarah Macleod Charles Goodwin Zara McKinlay	+44 (0)20 3004 9512 ananda@yellowjerseypr.com

https://investors.anandapharma.co.uk/link/mep3Xy

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAFLFVRVRILLIE